The University of Chicago Header Logo

Connection

George Bakris to Clinical Trials as Topic

Back to Details
This is a "connection" page, showing publications George Bakris has written about Clinical Trials as Topic.
George Bakris
Connection Strength
2.725
Clinical Trials as Topic
  1. Editorial perspective. Should microalbuminuria ever be considered as a renal endpoint in any clinical trial? Am J Nephrol. 2010; 31(5):469-70.
    View in: PubMed
    Score: 0.252
  2. Does evidence support renin-angiotensin system blockade for slowing nephropathy progression in elderly persons? Ann Intern Med. 2009 May 19; 150(10):731-3.
    View in: PubMed
    Score: 0.237
  3. The future of clinical trials in chronic renal disease: outcome of an NIH/FDA/Physician Specialist Conference. Evaluation of Clinical Trial Endpoints in Chronic Renal Disease Study Group. J Clin Pharmacol. 2000 Aug; 40(8):815-25.
    View in: PubMed
    Score: 0.129
  4. Prevalent and Incident Heart Failure in Cardiovascular Outcome Trials of Patients With Type 2 Diabetes. J Am Coll Cardiol. 2018 03 27; 71(12):1379-1390.
    View in: PubMed
    Score: 0.109
  5. Catheter-Based Renal Denervation for Resistant Hypertension: Will It Ever Be Ready for "Prime Time"? Am J Hypertens. 2017 Sep 01; 30(9):841-846.
    View in: PubMed
    Score: 0.105
  6. Nonsteroidal mineralocorticoid antagonists in diabetic kidney disease. Curr Opin Nephrol Hypertens. 2017 09; 26(5):368-374.
    View in: PubMed
    Score: 0.105
  7. Advances in treatment of hyperkalemia in chronic kidney disease. Expert Opin Pharmacother. 2015; 16(14):2205-15.
    View in: PubMed
    Score: 0.092
  8. Design considerations for clinical trials of autonomic modulation therapies targeting hypertension and heart failure. Hypertension. 2015 Jan; 65(1):5-15.
    View in: PubMed
    Score: 0.086
  9. Proceedings from Duke resistant hypertension think tank. Am Heart J. 2014 Jun; 167(6):775-88.e1.
    View in: PubMed
    Score: 0.082
  10. Effects of vascular endothelial growth factor signaling inhibition on human erythropoiesis. Oncologist. 2013; 18(8):965-70.
    View in: PubMed
    Score: 0.079
  11. Should ambulatory blood pressure monitoring be mandatory for future studies in resistant hypertension: a perspective. J Hypertens. 2012 May; 30(5):874-6.
    View in: PubMed
    Score: 0.073
  12. Fixed-dose combination and chronic kidney disease progression: which is the best? Curr Opin Nephrol Hypertens. 2010 Sep; 19(5):450-5.
    View in: PubMed
    Score: 0.065
  13. Pediatrics: blood pressure target for renoprotection in children. Nat Rev Nephrol. 2010 Feb; 6(2):67-8.
    View in: PubMed
    Score: 0.062
  14. Should proteinuria reduction be the criterion for antihypertensive drug selection for patients with kidney disease? Curr Opin Nephrol Hypertens. 2009 Sep; 18(5):386-91.
    View in: PubMed
    Score: 0.060
  15. Lower blood pressure goals for cardiovascular and renal risk reduction: are they defensible? J Clin Hypertens (Greenwich). 2009 Jul; 11(7):345-7.
    View in: PubMed
    Score: 0.060
  16. Effects of thiazolidinediones beyond glycaemic control. Curr Pharm Des. 2009; 15(5):529-36.
    View in: PubMed
    Score: 0.058
  17. Trials that matter: the effect of a fixed-dose combination of an Angiotensin-converting enzyme inhibitor and a diuretic on the complications of type 2 diabetes. Ann Intern Med. 2008 Mar 04; 148(5):400-1.
    View in: PubMed
    Score: 0.054
  18. Blood pressure control in the patient with difficult-to-control hypertension: which agent for which patient? Prev Cardiol. 2008; 11(1):42-9.
    View in: PubMed
    Score: 0.054
  19. The ADVANCE trial: further PROGRESS with HOPE. J Hum Hypertens. 2007 Dec; 21(12):911-3.
    View in: PubMed
    Score: 0.053
  20. ACE inhibitors and ARBs: are they better than other agents to slow nephropathy progression? J Clin Hypertens (Greenwich). 2007 Jun; 9(6):413-5.
    View in: PubMed
    Score: 0.052
  21. Antihypertensive agents, insulin sensitivity, and new-onset diabetes. Curr Diab Rep. 2007 Jun; 7(3):191-9.
    View in: PubMed
    Score: 0.052
  22. Is it time for a cardiovascular primary prevention trial in the elderly? Stroke. 2007 Feb; 38(2):441-50.
    View in: PubMed
    Score: 0.050
  23. Lessons learned from recent hypertension trials about kidney disease. Clin J Am Soc Nephrol. 2006 Mar; 1(2):229-35.
    View in: PubMed
    Score: 0.047
  24. Are chlorthalidone and hydrochlorothiazide equivalent blood-pressure-lowering medications? J Clin Hypertens (Greenwich). 2005 Jun; 7(6):354-6.
    View in: PubMed
    Score: 0.045
  25. Implications of albuminuria on kidney disease progression. J Clin Hypertens (Greenwich). 2004 Nov; 6(11 Suppl 3):18-22.
    View in: PubMed
    Score: 0.043
  26. Clinical importance of microalbuminuria in diabetes and hypertension. Curr Hypertens Rep. 2004 Oct; 6(5):352-6.
    View in: PubMed
    Score: 0.043
  27. What have we learned from the current trials? Med Clin North Am. 2004 Jan; 88(1):189-207.
    View in: PubMed
    Score: 0.041
  28. Comparing the effectiveness of glucose-lowering agents: real-world data to emulate a four-arm target trial. Lancet Diabetes Endocrinol. 2023 Dec; 11(12):892-894.
    View in: PubMed
    Score: 0.041
  29. Defining the antihypertensive properties of the angiotensin receptor blocker telmisartan by a practice-based clinical trial. Am J Hypertens. 2003 Jun; 16(6):460-6.
    View in: PubMed
    Score: 0.039
  30. ACE inhibitors and protection against kidney disease progression in patients with type 2 diabetes: what's the evidence. J Clin Hypertens (Greenwich). 2002 Nov-Dec; 4(6):420-3.
    View in: PubMed
    Score: 0.038
  31. Microalbuminuria: marker of vascular dysfunction, risk factor for cardiovascular disease. Vasc Med. 2002 Feb; 7(1):35-43.
    View in: PubMed
    Score: 0.036
  32. Novel Renal Autologous Cell Therapy for Type 2 Diabetes Mellitus Chronic Diabetic Kidney Disease: Clinical Trial Design. Am J Nephrol. 2022; 53(1):50-58.
    View in: PubMed
    Score: 0.036
  33. Type 2 diabetes: RENAAL and IDNT--the emergence of new treatment options. J Clin Hypertens (Greenwich). 2002 Jan-Feb; 4(1):52-7.
    View in: PubMed
    Score: 0.035
  34. Major adverse renal events (MARE): a proposal to unify renal endpoints. Nephrol Dial Transplant. 2021 02 20; 36(3):491-497.
    View in: PubMed
    Score: 0.033
  35. U.S. Prevalence of Individuals With Diabetes and Chronic Kidney Disease Indicated for SGLT-2 Inhibitor Therapy. J Am Coll Cardiol. 2020 12 15; 76(24):2907-2910.
    View in: PubMed
    Score: 0.033
  36. "Clinical pharmacology studies in patients with renal impairment: past experience and regulatory perspectives". J Clin Pharmacol. 2000 Jan; 40(1):7-10.
    View in: PubMed
    Score: 0.031
  37. Benefits of combination angiotensin-converting enzyme inhibitor and calcium antagonist therapy for diabetic patients. Am J Hypertens. 1999 Aug; 12(8 Pt 2):80S-85S.
    View in: PubMed
    Score: 0.030
  38. New approaches to hyperkalemia in patients with indications for renin angiotensin aldosterone inhibitors: Considerations for trial design and regulatory approval. Int J Cardiol. 2016 Aug 01; 216:46-51.
    View in: PubMed
    Score: 0.024
  39. Hypertension in diabetic patients: an update of interventional studies to preserve renal function. J Clin Pharmacol. 1995 Jan; 35(1):73-80.
    View in: PubMed
    Score: 0.022
  40. Diabetic kidney disease: a report from an ADA Consensus Conference. Am J Kidney Dis. 2014 Oct; 64(4):510-33.
    View in: PubMed
    Score: 0.021
  41. The past, present and future of renin-angiotensin aldosterone system inhibition. Int J Cardiol. 2013 Sep 01; 167(5):1677-87.
    View in: PubMed
    Score: 0.019
  42. Assessment and management of vascular disease risk in patients with chronic kidney disease. J Clin Lipidol. 2011 Jul-Aug; 5(4):251-60.
    View in: PubMed
    Score: 0.017
  43. Effects of diltiazem or lisinopril on massive proteinuria associated with diabetes mellitus. Ann Intern Med. 1990 May 01; 112(9):707-8.
    View in: PubMed
    Score: 0.016
  44. Combination therapy in hypertension. J Am Soc Hypertens. 2010 Jan-Feb; 4(1):42-50.
    View in: PubMed
    Score: 0.015
  45. Facts and fallacies of blood pressure control in recent trials: implications in the management of patients with hypertension. J Hypertens. 2009 Apr; 27(4):673-9.
    View in: PubMed
    Score: 0.015
  46. Thiazide-induced dysglycemia: call for research from a working group from the national heart, lung, and blood institute. Hypertension. 2008 Jul; 52(1):30-6.
    View in: PubMed
    Score: 0.014
  47. Antihypertensive efficacy of Irbesartan/HCTZ in men and women with the metabolic syndrome and type 2 diabetes. J Clin Hypertens (Greenwich). 2006 Jul; 8(7):470-80.
    View in: PubMed
    Score: 0.012
  48. Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. Hypertension. 2006 Aug; 48(2):219-24.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.